EMA colistin dosing strategy

Phase 3Small molecule

MMansoura University

EMA colistin dosing strategy is one of 5 small molecule programs targeting Infections. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

InfectionsRecruiting

InfectionsPhase 3

Recruiting

Competition

Competitive Landscape

6 competitors in Infections

#DrugCompanyPhaseTrials

Invanz

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

2 2

Temocillin

AAssistance Publique - Hôpitaux de Paris

Phase 3

1 3

EMA colistin dosing strategy

MMansoura University

Phase 3

1 4

Pentaglobin

MMedical University of Vienna

Phase 2

1 5

HLA-Matched Vsts

BBaylor College of Medicine

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Infections1 trial

Different Dosing Strategies of Colistin in Multidrug-Resistant Gram-Negative Bacilli Infections

Recruiting·MMansoura University·Phase 2/3·NCT06843668·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for EMA colistin dosing strategy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EMA colistin dosing strategy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EMA colistin dosing strategy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mansoura University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMansoura University

EMA colistin dosing strategy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Infections1 trial

References

Drug Info

Quick Facts

Related News